Postoperative Adjuvant Imatinib Therapy-Associated Nomogram to Predict Overall Survival of Gastrointestinal Stromal Tumor

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Apr 1

PMID 35360729

Authors

Xuechao Liu

Enyu Lin

Yuqi Sun

Xiaodong Liu

Zequn Li

Xuelong Jiao

Yi Li

Dong Guo

Peng Zhang

Xingyu Feng

Tao Chen

Zhaojian Niu

Zhiwei Zhou

Haibo Qiu

Yanbing Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Adjuvant imatinib therapy has been shown to improve overall survival (OS) of gastrointestinal stromal tumor (GIST) significantly. Few nomograms combining the use of adjuvant imatinib and clinicopathological characteristics estimate the outcome of patients. We aimed to establish a more comprehensive nomogram for predicting OS in patients with GIST.

Methods: In total, 1310 GIST patients undergoing curative resection at four high-volume medical centers between 2001 and 2015 were enrolled. Independent prognostic factors were identified by multivariate Cox analysis. Eligible patients were randomly assigned in a ratio of 7:3 into a training set (916 cases) and a validation set (394 cases). A nomogram was established by R software and its predictive power compared with that of the modified National Institutes of Health (NIH) classification using time-dependent receiver operating characteristic (ROC) curves and calibration plot.

Results: Age, tumor site, tumor size, mitotic index, postoperative imatinib and diagnostic delay were identified as independent prognostic parameters and used to construct a nomogram. Of note, diagnostic delay was for the first time included in a prognostic model for GIST. The calibrated nomogram resulted in predicted survival rates consistent with observed ones. And the decision curve analysis suggested that the nomogram prognostic model was clinically useful. Furthermore, time-dependent ROC curves showed the nomogram exhibited greater discrimination power than the modified NIH classification in 3- and 5-year survival predictions for both training and validation sets (all < 0.05).

Conclusions: Postoperative adjuvant imatinib therapy improved the survival of GIST patients. We developed and validated a more comprehensive prognostic nomogram for GIST patients, and it could have important clinical utility in improving individualized predictions of survival risks and treatment decision-making.

Citing Articles

Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor.

Ran P, Tan T, Zhou H, Li J, Yang H, Li J J Pers Med. 2023; 13(3).

PMID: 36983680 PMC: 10052207. DOI: 10.3390/jpm13030498.

Development and validation of a prognostic model to predict the prognosis of patients with colorectal gastrointestinal stromal tumor: A large international population-based cohort study.

Li Y, Zhang Y, Fu Y, Yang W, Wang X, Duan L Front Oncol. 2022; 12:1004662.

PMID: 36408151 PMC: 9666406. DOI: 10.3389/fonc.2022.1004662.

Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender.

Ran P, Li J, Wu X, Yang H, Zhang J Patient Prefer Adherence. 2022; 16:2077-2087.

PMID: 35989973 PMC: 9384372. DOI: 10.2147/PPA.S376843.

References

Diamand R, Ploussard G, Roumiguie M, Oderda M, Benamran D, Fiard G . External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol. 2020; 79(2):180-185. DOI: 10.1016/j.eururo.2020.09.037. View

Pita-Fernandez S, Gonzalez-Saez L, Lopez-Calvino B, Seoane-Pillado T, Rodriguez-Camacho E, Pazos-Sierra A . Effect of diagnostic delay on survival in patients with colorectal cancer: a retrospective cohort study. BMC Cancer. 2016; 16:664. PMC: 4994409. DOI: 10.1186/s12885-016-2717-z. View

Miettinen M, Lasota J . Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2):70-83. DOI: 10.1053/j.semdp.2006.09.001. View

Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-9. DOI: 10.1016/j.humpath.2008.06.025. View

Lin Y, Wang M, Jia J, Wan W, Wang T, Yang W . Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts. EBioMedicine. 2020; 60:103016. PMC: 7522759. DOI: 10.1016/j.ebiom.2020.103016. View

Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G . New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019; 11:1758835919841946. PMC: 6535752. DOI: 10.1177/1758835919841946. View

Qiu Q, Duan J, Deng H, Han Z, Gu J, Yue N . Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery. Front Oncol. 2020; 10:1398. PMC: 7431604. DOI: 10.3389/fonc.2020.01398. View

Cao X, Cui J, Yu T, Li Z, Zhao G . Fibrinogen/Albumin Ratio Index Is an Independent Prognosis Predictor of Recurrence-Free Survival in Patients After Surgical Resection of Gastrointestinal Stromal Tumors. Front Oncol. 2020; 10:1459. PMC: 7462001. DOI: 10.3389/fonc.2020.01459. View

Liegl-Atzwanger B, Fletcher J, Fletcher C . Gastrointestinal stromal tumors. Virchows Arch. 2010; 456(2):111-27. DOI: 10.1007/s00428-010-0891-y. View

10.

Heinrich M, Rankin C, Blanke C, Demetri G, Borden E, Ryan C . Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017; 3(7):944-952. PMC: 5727908. DOI: 10.1001/jamaoncol.2016.6728. View

11.

Joensuu H, Eriksson M, Hall K, Reichardt A, Hartmann J, Pink D . Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2015; 34(3):244-50. DOI: 10.1200/JCO.2015.62.9170. View

12.

Wu C, Tzen C, Wang S, Yeh C . Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers (Basel). 2019; 11(5). PMC: 6563074. DOI: 10.3390/cancers11050679. View

13.

Vickers A, Cronin A, Elkin E, Gonen M . Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008; 8:53. PMC: 2611975. DOI: 10.1186/1472-6947-8-53. View

14.

Ge X, Lei L, Ge F, Jiang X . Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database. Scand J Gastroenterol. 2019; 54(4):480-484. DOI: 10.1080/00365521.2019.1604798. View

15.

Vickers A, Elkin E . Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26(6):565-74. PMC: 2577036. DOI: 10.1177/0272989X06295361. View

16.

Liu M, Song C, Zhang P, Fang Y, Han X, Li J . A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors. Med Sci Monit. 2020; 26:e922378. PMC: 7268888. DOI: 10.12659/MSM.922378. View

17.

Wu J, Zhang H, Li L, Hu M, Chen L, Xu B . A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. Cancer Commun (Lond). 2020; 40(7):301-312. PMC: 7365459. DOI: 10.1002/cac2.12067. View

18.

Elfgen C, Varga Z, Reeve K, Moskovszky L, Bjelic-Radisic V, Tausch C . The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. Breast Cancer Res Treat. 2019; 177(1):67-75. DOI: 10.1007/s10549-019-05298-6. View

19.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Hall K, Reichardt A . Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017; 3(5):602-609. PMC: 5470395. DOI: 10.1001/jamaoncol.2016.5751. View

20.

Patel D, Lutfi W, Eguia E, Sweigert P, Knab L, Abood G . Adjuvant systemic therapy for small bowel gastrointestinal stromal tumor (GIST): Is there a survival benefit after R0 resection?. Surgery. 2020; 168(4):695-700. DOI: 10.1016/j.surg.2020.04.069. View